QA Manager Sent to Puerto Rico Drug-Making Plant to Deal with Violation Problem

In 2002, pharmaceutical Company GlaxoSmithKline PLC sent Cheryl Eckard to Puerto Rico to tackle the violation problem in one of its biggest drug-making plants.

The U. S. authorities had warned that the plant is not abiding by the standards to make drugs and ointments, including one that was made to treat skin-related infections in children.

Ms. Eckard has received that the largest amount of payment or reward for whistleblowing so far in the history of the United States.

Ms. Eckard is slated to receive around $96 million helping the Government in securing a criminal guilty plea and about $750 million payment from Glaxo for initiating an inquest of manufacturing deficiencies.

Joseph E. B. White, legal representative of whistleblowers said, "The breadth of cases has expanded to include different areas we've never seen before".

Glaxo, on the other hand, has expressed regret over the way it conducted the operation in the Puerto Rico plant, which is since then not functioning.

Glaxo owned up that it sold contaminated products with the aim to deceive or misinform. The date for the court case against the Company has not yet been decided.

The United States Attorney for Massachusetts, Carmen M. Ortiz refused to comment on the case as it is still under investigation.